Quidel Lyra Influenza A+B Assay

Fast, accurate, and ready-to-use reagents

The Quidel™ Lyra™ Influenza A+B Assay is available as a molecular diagnostic kit validated for *in vitro* diagnostic use on both the Applied Biosystems™ QuantStudio™ Dx and the 7500 Fast Dx real-time PCR instruments.

Thermo Fisher Scientific has partnered with Quidel to make available a real-time PCR assay that is:

- Fast—complete master mix prep in one quick 135 µL transfer of rehydration buffer
- Accurate—excellent results with multiple sample types
- Ready to use—lyophilized master mix and sample preparation performed at room temperature, eliminating the need for ice during processing



Influenza virus

About the Quidel Lyra Influenza A+B Assay kits

Validated for both the QuantStudio Dx and the 7500 Fast Dx real-time PCR instruments, Quidel Lyra Influenza A+B Assay kits are designed for the qualitative detection and identification of influenza A and influenza B viral nucleic acids using real-time PCR.

In a head-to-head clinical study with over 600 patient samples, the Quidel Lyra Influenza A+B assay was more sensitive and specific and less prone to inhibition than one of the US market-leading molecular tests [1], and:

- Yielded 5% more positive influenza A results, as resolved by sequencing
- Exhibited an inhibition rate four times greater than that of the competitor's assay
- Was successfully tested against 50 strains of influenza, including H1N1, H7N9, and H3N2 influenza
- Was tested using common respiratory specimens
- Was developed using common fluors

ThermoFisher SCIENTIFIC

applied biosystems

Workflow benefits of Quidel Lyra Influenza A+B Assay kits

Feature	Benefit
One-step reagent setup	Rehydration solution is simply added to the lyophilized master mix
Speed	Results typically in less than 75 minutes after extraction
Easy training	Simplified and uniform workflow with standard pipetting volumes
Refrigerated storage	No freezer needed (2–8°C storage)
Long shelf life	2-year shelf life from date of manufacture
Room temperature setup	No ice or cooling block required
Flexible 96-test format	Kit includes 12 x 8 vials of master mix, rehydration solution, and liquid process controls
Multi-well panels	Standard thermal cycling conditions allow for batches with many multiplexed assays, effectively providing a panel of results
Common internal control	Extracted samples can be used with other assays in the product family

Performance evaluation

Influenza A			
Fresh nasal/nasopharyngeal swab (N = 668)	Competitive FDA-cleared real-time PCR device		
Quidel Lyra Influenza A+B Assay	Positive	Negative	Total
Positive	139	8*	147
Negative	0	521	521
Total	139	529	668
			95% Confidence interval
Positive % agreement	139/139	100%	97.4% to 100%
Negative % agreement	521/529	98.5%	97.0% to 99.3%

*Seven specimens were negative by FDA-cleared real-time PCR device, but positive for influenza A by sequence analysis. One specimen was negative by FDA-cleared real-time PCR device and negative for influenza A by sequence analysis.

Performance evaluation

Influenza B			
Fresh nasal/nasopharyngeal swab (N = 668)	Competitive FDA-cleared real-time PCR device		
Quidel Lyra Influenza A+B Assay	Positive	Negative	Total
Positive	105	12†	117
Negative	5	546	551
Total	110	558	668
			95% Confidence interval
Positive % agreement	105/110	95.5%	89.7% to 98.5%
Negative % agreement	546/558	97.8%	96.3% to 98.9%

†Twelve specimens were negative by FDA-cleared real-time PCR device, but positive for influenza B by sequence analysis.

Ordering information

Product	Quantity	Cat. No.
Quidel Lyra Influenza A+B Assay	96 reactions	4472081

To order or to get more information, go to
thermofisher.com/quidelassays

ThermoFisher SCIENTIFIC

1. Quidel internal information.